Dan T. Vogl, MD: Selinexor Plus Low-Dose Dexamethasone in “Penta-Refractory” Myeloma Patients

Heavily-refractory myeloma patients who have exhausted available treatment agents were able to achieve a response with the investigational agent selinexor. Dr. Vogl shares results of the phase II STORM study.

SHARE